| Basics |
Nektar Therapeutics
Nektar Therapeutics Inc is a biopharmaceutical company engaged in the development of new molecules to treat diseases with unmet medical needs. The company is researching and developing drugs for treating cancer, auto-immune disease and chronic pain.
|
| IPO Date: |
May 3, 1994 |
| Sector: |
Healthcare |
| Industry: |
Pharma |
| Market Cap: |
$125.53M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.36 | 2.55%
|
| Avg Daily Range (30 D): |
$0.03 | 4.26%
|
| Avg Daily Range (90 D): |
$0.03 | 4.27%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1.45M |
| Avg Daily Volume (30 D): |
1.6M |
| Avg Daily Volume (90 D): |
1.9M |
| Trade Size |
| Avg Trade Size (Sh.): |
168 |
| Avg Trade Size (Sh.) (30 D): |
296 |
| Avg Trade Size (Sh.) (90 D): |
312 |
| Institutional Trades |
| Total Inst.Trades: |
8,952 |
| Avg Inst. Trade: |
$2.66M |
| Avg Inst. Trade (30 D): |
$.62M |
| Avg Inst. Trade (90 D): |
$.62M |
| Avg Inst. Trade Volume: |
.12M |
| Avg Inst. Trades (Per Day): |
2 |
| Market Closing Trades |
| Avg Closing Trade: |
$4.94M |
| Avg Closing Trade (30 D): |
$.73M |
| Avg Closing Trade (90 D): |
$.73M |
| Avg Closing Volume: |
220.53K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.63
|
$-.24
|
$.04
|
|
Diluted EPS
|
$-.63
|
$-.24
|
$.04
|
|
Revenue
|
$ 87.25M
|
$ 10.46M
|
$ 29.18M
|
|
Gross Profit
|
$
|
$
|
$ 21.2M
|
|
Net Income / Loss
|
$ -133.04M
|
$ -50.88M
|
$ 7.26M
|
|
Operating Income / Loss
|
$ -114.31M
|
$ -44.54M
|
$ 14.35M
|
|
Cost of Revenue
|
$ 22.15M
|
$ M
|
$ 7.98M
|
|
Net Cash Flow
|
$ -9.75M
|
$ -5.36M
|
$ 14.14M
|
|
PE Ratio
|
|
|
|
|
